摘要
对１３２例肺癌病人采用ＣＥ方案治疗２个或３个周期，观察疗效和毒副反应。总有效率为４７．０％，其中小细胞肺癌３７例，有效率为８３．８％，腺癌６２例，有效率为３３．９％，鳞癌３３例，有效率为３０．３％。毒副反应主要是骨髓抑制，消化道及肝肾毒性较轻。结果表明，ＣＥ方案治疗小细胞肺癌可获得较高疗效，对非小细胞肺癌的疗效与其它常用方案相近，毒副反应较轻。
cases of lung cancer patients were treated by CE(carboplatin and Etoposide,vp-16) regimen for 2 or 3 cycles,the effect and toxicity were observed, The total response rate is 47.0%,Among them,37 cases are SCLC, response rate is 83.8%; 62 cases are adenocarcinoma, response rate is 33.9%; 33 cases are squemous cancer, response rate is 30.3%. The main toxicity is myelosuppression. Digestal, hepatal and renal toxicity is mild. The result shows that the CE regimen gives a higher treatment effect in SCLC and similar response rate in NSCLC compared with other combined chemotherapy, the toxicity and side effect is mild.
出处
《实用癌症杂志》
1997年第2期137-138,共2页
The Practical Journal of Cancer
